Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma

Leukemia and Lymphoma

Volumn 56, Issue 12, 2015, Pages 3418-3425

  Gracheva, Marina A ^a   Urnova, Evdokiya S ^a   Sinauridze, Elena I ^a   Tarandovskiy, Ivan D ^a   Orel, Elena B ^a   Poletaev, Alexander V ^a   Mendeleeva, Larisa P ^a   Ataullakhanov, Fazoil I ^a,b,c,d,e   Balandina, Anna N ^a,b  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^c HemaCore LLC   (Russian Federation)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

Author keywords

Chemotherapy; hypercoagulability; multiple myeloma; thrombin generation test; thrombodynamics; thromboelastography

Indexed keywords

CYCLOPHOSPHAMIDE; D DIMER; HEPARIN; THROMBIN; ANTICOAGULANT AGENT;

ABSORPTION LAG TIME; ABSORPTION PARAMETERS; ADULT; AGED; AGRANULOCYTOSIS; ANTICOAGULANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG TREATMENT FAILURE; FEMALE; HEMODYNAMICS; HEMOSTASIS; HEMOSTASIS TESTING SYSTEM; HEPARINIZATION; HUMAN; HYPERCOAGULABILITY; HYPOCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBODYNAMICS; THROMBOELASTOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; COMPLICATION; MIDDLE AGED; REMISSION; THROMBOPHILIA; THROMBOSIS;

ADULT; AGED; AGRANULOCYTOSIS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; THROMBELASTOGRAPHY; THROMBIN TIME; THROMBOPHILIA; THROMBOSIS;

EID: 84941877813     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1041385     Document Type: Article

References (35)

1. Catovsky D, Ikoku NB, Pitney WR, et al. Thromboembolic complications in myelomatosis. BMJ 1970; 3: 438-439.
2. Kristinsson SY. Thrombosis in multiple myeloma. Am Soc Hematol Educ Program 2010: 437-444.
3. Libourel EJ, Sonneveld P, van der Holt B, et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010; 116: 22-26.
4. Auwerda JJA, Sonneveld P, de Maat MPM, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92: 279-280.
5. Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399-405.
6. Jiménez-Zepeda VH, Domínguez-Martínez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 4: 11.
7. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007; 7: 307-315.
8. Zamagni E, Brioli A, Tacchetti P, et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011; 37: 209-219.
9. Van Marion AMW, Auwerda JJA, Minnema MC, et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005; 94: 1341-1343.
10. Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010; 115: 4991-4998.
11. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112: 3582-3586.
12. Snowden JA, Ahmedzai SH, Ashcroft J, et al. and Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011; 154: 76-103.
13. Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol 2011; 33: 333-342.
14. Toukh M, Siemens DR, Black A, et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014; 133: 88-95.
15. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Am Soc Clin Oncol 2011; 29: 2099-2103.
16. Treliński J, Misiewicz M, Robak M, et al. Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 2014; 133: 667-670.
17. Lipets E, Vlasova O, Urnova E, et al. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PloS One 2014; 9: e87692.
18. Seregina EA, Nikulina OF, Tsvetaeva NV, et al. Laboratory tests for coagulation system monitoring in a patient with β-thalassemia. Int J Hematol 2014; 99: 588-596.
19. Soshitova NP, Karamzin SS, Balandina AN, et al. Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis 2012; 23: 498-507.
20. Ovanesov MV, Lopatina EG, Saenko EL, et al. Effect of factor VIII on tissue factor-initiated spatial clot growth. Thromb Haemost 2003; 89: 235-242.
21. Panteleev MA, Ovanesov MV, Kireev DA, et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 2006; 90: 1489-1500.
22. Tarandovskiy ID, Balandina AN, Kopylov KG, et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 2013; 131: e274-280.
23. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127 (Suppl. 3): S21-25.
24. Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008; 142: 250-256.
25. Robak M, Treliński J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol (Lond) 2012; 29: 3574-3580.
26. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997; 157: 2475-2479.
27. Al Dieri R, Alban S, Béguin S, et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-1401.
28. Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol 2000; 113: 725-731.
29. Muedra V, Bonanad S, Gómez M, et al. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Perfusion 2011; 26: 487-495.
30. Fries D. Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 1946 2011; 161: 68-72.
31. Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010; 149: 613-619.
32. Ranucci M, Isgrò G, Cazzaniga A, et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14: 437-442.
33. Urbauer E, Kaufmann H, Nösslinger T, et al. Thromboembolic events during treatment with thalidomide. Blood 2002; 99: 4247-4248.
34. Lejhancova-Tousovska K, Zapletal O, Vytiskova S, et al. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. Blood Coagul Fibrinolysis 2012; 23: 144-154.
35. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001; 19: 1137-1146.